ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
티센트릭(우스테키누맙) 시장 규모는 최근 급성장하고 있습니다. 2025년 436만 달러에서 2026년에는 489만 달러에 이르고, CAGR 12.2%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 화학요법의 한계, 획기적인 면역요법의 승인, 암 발병률 증가, PD-L1 억제제의 임상적 성공, 병원 중심의 암 치료 등의 요인에 기인하는 것으로 보입니다.
티센트릭(우스테키누맙) 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 765만 달러에 이르고, CAGR은 11.8%를 나타낼 전망입니다. 예측 기간 동안의 성장은 종양학 임상시험 증가, 바이오마커 기반 치료의 확대, 암 검진율 증가, 종양학 분야에 대한 헬스케어 투자 증가, 생존율 향상에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 면역관문억제제 도입 증가, 여러 암종에 대한 적응증 확대, 병용 면역요법 사용 증가, 정밀 종양학 접근법의 성장, 개인 맞춤형 암 치료로의 전환 등을 꼽을 수 있습니다.
암 발병률 증가는 향후 몇 년 동안 테센트릭(아테졸리주맙) 시장의 성장을 견인할 것으로 예측됩니다. 암 환자 수 증가는 고령화, 검진 기술의 발전, 생활습관의 변화, 환경적 요인에 대한 노출, 생존율의 향상 등의 요인에 기인하며, 이 모든 것이 더 많은 사람들이 암 진단을 받고 암과 함께 살아가는 상황에 기여하고 있습니다. 테센트릭(아테졸리주맙)은 면역체계를 활용하여 암세포를 표적으로 하는 암 치료에서 중요한 역할을 합니다. 종양이 면역의 감지를 피할 수 있게 하는 단백질인 PD-L1을 억제하여 T세포가 암세포를 보다 효과적으로 인식하고 파괴할 수 있게 합니다. 예를 들어, 2024년 1월 미국 비영리단체인 미국암협회가 발표한 자료에 따르면, 2024년 신규 암 발병 건수는 2023년 195만 8,310건에서 200만 1,140건으로 2.19% 증가할 것으로 예상했습니다. 이러한 암 환자 증가 추세는 테센트릭(아테졸리주맙) 시장의 성장을 견인하고 있습니다.
테센트릭(아테졸리주맙) 시장의 주요 동향으로는 정맥주사 제형, 피하주사 제형 등 혁신적인 제형 개발이 꼽힙니다. 이는 정확한 투여량, 빠른 전신 흡수, 안정적인 치료 약물 농도를 보장하기 위한 것입니다. 정맥주사 제제는 전신암 치료에서 단클론 항체를 정맥주사를 통해 효율적으로 전달합니다. 예를 들어, 2024년 9월 미국 생명공학 기업 젠젠텍은 아테졸리주맙과 히알루로니다제-tqjs의 피하주사제에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. 테센트릭은 미국에서 승인된 최초의 피하투여형 항 PD-L1 치료제로, IMscin001 임상에서 입증된 바와 같이 약물의 노출량과 전체 약효는 동일하게 유지하면서 정맥주입에 필요한 30-60분 대비 약 7분이라는 짧은 투여 시간을 제공합니다. 이 약은 비소세포폐암(NSCLC), 소세포폐암(SCLC), 흑색종, 간세포암, 폐포성 연부육종 등 다양한 성인 암에 대한 적응증을 보유하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 시장 규제 상황과 투자환경
제29장 경쟁 구도와 기업 개요
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 시장 잠재력이 높은 국가, 부문, 전략
제33장 부록
LSH
영문 목차
영문목차
Tecentriq (Atezolizumab) is a monoclonal antibody immunotherapy that belongs to the class of immune checkpoint inhibitors. It specifically targets programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 or B7.1 receptors on T-cells. This inhibition reactivates the immune system, allowing T-cells to recognize and destroy cancer cells.
The main types of Tecentriq (Atezolizumab) include PD-L1 inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, immunomodulators, and others. The PD-L1 inhibitor form of Tecentriq is a monoclonal antibody that blocks PD-L1, preventing it from suppressing the immune response against cancer cells. It is indicated for lung cancer, bladder cancer, melanoma, Hodgkin's lymphoma, head and neck cancer, and other malignancies. Tecentriq is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used by a range of end users, including hospitals, homecare services, and specialty clinics.
Tariffs have impacted the tecentriq market by increasing costs related to imported biologic substances, formulation reagents, and infusion delivery systems. These increases have affected oncology treatment budgets, particularly in hospital and specialty clinic settings. Regions such as asia-pacific and latin america are more exposed due to reliance on imported immunotherapies. At the same time, tariffs have supported local biologics production initiatives, strengthened oncology supply resilience, and encouraged long-term investment in cancer treatment infrastructure.
The tecentriq (atezolizumab) market research report is one of a series of new reports from The Business Research Company that provides tecentriq (atezolizumab) market statistics, including tecentriq (atezolizumab) industry global market size, regional shares, competitors with a tecentriq (atezolizumab) market share, detailed tecentriq (atezolizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the tecentriq (atezolizumab) industry. This tecentriq (atezolizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tecentriq (atezolizumab) market size has grown rapidly in recent years. It will grow from $4.36 million in 2025 to $4.89 million in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to limitations of chemotherapy, breakthrough immunotherapy approvals, rising cancer incidence, clinical success of pd-l1 inhibitors, hospital-centered oncology care.
The tecentriq (atezolizumab) market size is expected to see rapid growth in the next few years. It will grow to $7.65 million in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to growth in oncology clinical trials, expansion of biomarker-based treatment, increased cancer screening rates, rising healthcare investment in oncology, improved survival outcomes. Major trends in the forecast period include rising adoption of immune checkpoint inhibitors, expansion of indications across multiple cancers, increased use of combination immunotherapy, growth in precision oncology approaches, shift toward personalized cancer treatment.
The rising prevalence of cancer is expected to drive the growth of the Tecentriq (atezolizumab) market in the coming years. The increasing number of cancer cases is attributed to factors such as an aging population, improved detection methods, lifestyle changes, environmental exposures, and better survival rates, all of which contribute to more people being diagnosed and living with cancer. Tecentriq (atezolizumab) plays a crucial role in cancer management by harnessing the immune system to target cancer cells. It blocks PD-L1, a protein that allows tumors to evade immune detection, enabling T-cells to recognize and destroy cancer cells more effectively. For instance, in January 2024, the American Cancer Society, a US-based nonprofit organization, reported that cancer cases rose to 2,001,140, compared to 1,958,310 in 2023, reflecting a 2.19% increase. Consequently, the rising prevalence of cancer is driving the Tecentriq (atezolizumab) market.
A key trend in the Tecentriq (atezolizumab) market is the development of innovative formulations, such as intravenous and subcutaneous preparations, to ensure precise dosing, rapid systemic absorption, and consistent therapeutic levels. The intravenous formulation delivers the monoclonal antibody efficiently via infusion for systemic cancer treatment. For example, in September 2024, Genentech Inc., a US-based biotechnology company, received U.S. Food and Drug Administration approval for atezolizumab and hyaluronidase-tqjs for subcutaneous injection. Tecentriq became the first subcutaneous anti-PD-L1 therapy approved in the U.S., offering a faster administration time of approximately 7 minutes compared to the 30-60 minutes required for intravenous infusion, while maintaining comparable efficacy in drug exposure and overall response rates, as demonstrated in the IMscin001 trial. It is indicated for multiple adult cancers, including NSCLC, SCLC, melanoma, hepatocellular carcinoma, and alveolar soft part sarcoma.
In October 2024, Lonza Group AG, a Switzerland-based pharmaceutical, biotechnology, and nutrition company, acquired Roche's Vacaville large-scale biologics manufacturing facility for $1.2 billion. This acquisition strengthens Lonza's West Coast commercial manufacturing presence near San Francisco's biotech hub, complementing its East Coast site in Portsmouth, New Hampshire, and its global network across Europe and the Asia Pacific. The expansion enhances Lonza's ability to manufacture late-stage clinical and commercial products and support the production of new molecules approaching commercialization. Roche Holding AG, also based in Switzerland, is a leading manufacturer of pharmaceuticals and biologics, including Tecentriq (atezolizumab).
Major companies operating in the tecentriq (atezolizumab) market are Roche Holding AG, Chugai Pharmaceutical Co. Ltd
North America was the largest region in the tecentriq (atezolizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tecentriq (atezolizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the tecentriq (atezolizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
The tecentriq (atezolizumab) market consists of sales of biosimilars, immuno-oncology pipeline drugs, supportive oncology medications and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tecentriq (Atezolizumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses tecentriq (atezolizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for tecentriq (atezolizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tecentriq (atezolizumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Class: PD-L1 Inhibitors; PD-1 Inhibitors; CTLA-4 Inhibitors; Immunomodulators; Other Drug Classes
2) By Clinical Indication: Lung Cancer; Bladder Cancer; Melanoma; Hodgkin's Lymphoma; Head And Neck Cancer; Other Indications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.1 Rising Adoption Of Immune Checkpoint Inhibitors
4.2.2 Expansion Of Indications Across Multiple Cancers
4.2.3 Increased Use Of Combination Immunotherapy
4.2.4 Growth In Precision Oncology Approaches
4.2.5 Shift Toward Personalized Cancer Treatment
5. Tecentriq (Atezolizumab) Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Oncology Clinics
5.3 Specialty Cancer Centers
5.4 Homecare Providers
5.5 Research Institutions
6. Tecentriq (Atezolizumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Tecentriq (Atezolizumab) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Tecentriq (Atezolizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Tecentriq (Atezolizumab) Market Size, Comparisons And Growth Rate Analysis
7.3. Global Tecentriq (Atezolizumab) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Tecentriq (Atezolizumab) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Tecentriq (Atezolizumab) Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Tecentriq (Atezolizumab) Market Segmentation
9.1. Global Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
PD-L1 Inhibitors, PD-1 Inhibitors, CTLA-4 Inhibitors, Immunomodulators, Other Drug Classes
9.2. Global Tecentriq (Atezolizumab) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Lung Cancer, Bladder Cancer, Melanoma, Hodgkin's Lymphoma, Head And Neck Cancer, Other Indications
9.3. Global Tecentriq (Atezolizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Tecentriq (Atezolizumab) Market
12.1. China Tecentriq (Atezolizumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Tecentriq (Atezolizumab) Market
13.1. India Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Tecentriq (Atezolizumab) Market
14.1. Japan Tecentriq (Atezolizumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Tecentriq (Atezolizumab) Market
15.1. Australia Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. South Korea Tecentriq (Atezolizumab) Market
16.1. South Korea Tecentriq (Atezolizumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
16.2. South Korea Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. Western Europe Tecentriq (Atezolizumab) Market
17.1. Western Europe Tecentriq (Atezolizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. Western Europe Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. UK Tecentriq (Atezolizumab) Market
18.1. UK Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. Germany Tecentriq (Atezolizumab) Market
19.1. Germany Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. France Tecentriq (Atezolizumab) Market
20.1. France Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. Eastern Europe Tecentriq (Atezolizumab) Market
21.1. Eastern Europe Tecentriq (Atezolizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
21.2. Eastern Europe Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. North America Tecentriq (Atezolizumab) Market
22.1. North America Tecentriq (Atezolizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
22.2. North America Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. USA Tecentriq (Atezolizumab) Market
23.1. USA Tecentriq (Atezolizumab) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
23.2. USA Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
24.2. Canada Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. South America Tecentriq (Atezolizumab) Market
25.1. South America Tecentriq (Atezolizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
25.2. South America Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Middle East Tecentriq (Atezolizumab) Market
26.1. Middle East Tecentriq (Atezolizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Middle East Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Africa Tecentriq (Atezolizumab) Market
27.1. Africa Tecentriq (Atezolizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
27.2. Africa Tecentriq (Atezolizumab) Market, Segmentation By Drug Class, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. Tecentriq (Atezolizumab) Market Regulatory and Investment Landscape
29. Tecentriq (Atezolizumab) Market Competitive Landscape And Company Profiles
29.1. Tecentriq (Atezolizumab) Market Competitive Landscape And Market Share 2024
29.1.1. Top 10 Companies (Ranked by revenue/share)
29.2. Tecentriq (Atezolizumab) Market - Company Scoring Matrix
29.2.1. Market Revenues
29.2.2. Product Innovation Score
29.2.3. Brand Recognition
29.3. Tecentriq (Atezolizumab) Market Company Profiles
29.3.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
29.3.2. Chugai Pharmaceutical Co. Ltd Overview, Products and Services, Strategy and Financial Analysis
30. Global Tecentriq (Atezolizumab) Market Competitive Benchmarking And Dashboard
31. Key Mergers And Acquisitions In The Tecentriq (Atezolizumab) Market
32. Tecentriq (Atezolizumab) Market High Potential Countries, Segments and Strategies
32.1 Tecentriq (Atezolizumab) Market In 2030 - Countries Offering Most New Opportunities
32.2 Tecentriq (Atezolizumab) Market In 2030 - Segments Offering Most New Opportunities
32.3 Tecentriq (Atezolizumab) Market In 2030 - Growth Strategies
32.3.1 Market Trend Based Strategies
32.3.2 Competitor Strategies
33. Appendix
33.1. Abbreviations
33.2. Currencies
33.3. Historic And Forecast Inflation Rates
33.4. Research Inquiries
33.5. The Business Research Company
33.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
